CoChat

Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non–Small-Cell Lung Cancer

Open access
Menter, Alex R., Carroll, Nikki M., Sakoda, Lori C., Delate, Thomas, Hornbrook, Mark C., Jain, Rakesh K., Kushi, Lawrence H., Quinn, Virginia P., Ritzwoller, Debra P. · 2017 · Clinical Lung Cancer
Cited by 37

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Introduction Preclinical studies suggest that angiotensin system inhibitors (ASI) and bevacizumab improve tumor perfusion and chemotherapy efficacy. We performed a retrospective study to examine whether concomitant ASI use during carboplatin and paclitaxel (CP) without or with bevacizumab (CPB) was associated with improved overall survival (OS) in patients with advanced nonsquamous, non–small‐cell lung cancer (NS‐NSCLC). Patients and Methods In a retrospective cohort study, adult patients diagnosed with stage IIIB or IV NS‐NSCLC between 2005 and 2011 were identified from tumor registries at 1 of 4 Kaiser Permanente regions. Survival differences between those who did and did not receive ASIs concomitant with chemotherapy (CP or CPB) were assessed using propensity score–matched proportional hazard models. OS was measured from the initiation of chemotherapy until death, disenrollment, or December 31, 2012. Results Of the 1465 CP and 348 CPB patients included, 273 (19%) and 78 (22%), respectively, received concomitant ASI. For CP patients with and without concomitant ASI exposure, median OS was 12.0 and 8.4 months, respectively (crude hazard ratio [HR], 0.72; 95% confidence interval [CI], 0.63‐0.84). For CPB patients, the comparable median OS was 14.9 and 11.9 months, respectively (crude HR, 0.77; 95% CI, 0.57‐1.02). Using propensity score–matched cohorts, the HR for concomitant ASI use was 0.73 (95% CI, 0.61‐0.88) for CP patients and 0.79 (95% CI, 0.51‐1.21) for CPB patients. Conclusion Concomitant ASI receipt during CP or CPB therapy for NS‐NSCLC was associated with improved survival, although the association was only statistically significant in the CP group. Micro‐Abstract Preclinical studies suggest that angiotensin system inhibitors (ASI) improve tumor perfusion and chemotherapy delivery. In a retrospective study of nearly 2000 patients with advanced non–small‐cell lung cancer, concomitant ASI receipt during carboplatin and paclitaxel (CP) without or with bevacizumab (CPB) for nonsquamous, non–small‐cell lung cancer was associated with improved survival, although the association was only statistically significant in the CP group.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cllc.2016.07.008

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 37

Metadata

Authors
Menter, A. R., Carroll, N. M., Sakoda, L. C., Delate, T., Hornbrook, M. C., Jain, R. K., Kushi, L. H., Quinn, V. P., & Ritzwoller, D. P.
Venue
Clinical Lung Cancer
Publisher
Elsevier BV
Published
2017-03
Volume
18
Issue
2
Pages
189-197.e3
ISSN
1525-7304 (ISSN-L)
OpenAlex
W2509882972
Cited by
37
References
6
FWCI
3.71
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non–Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1016/j.cllc.2016.07.008
The paper
Menter, A. R., Carroll, N. M., Sakoda, L. C., Delate, T., Hornbrook, M. C., Jain, R. K., Kushi, L. H., Quinn, V. P., & Ritzwoller, D. P. (2017). Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2016.07.008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.